Warfarin anticoagulation after total hip or total knee replacement: clinical and resource-utilization outcomes in a university-based antithrombosis clinic.

PURPOSE Clinical and resource-utilization outcomes associated with warfarin anticoagulation after major orthopedic surgery were evaluated. METHODS Consecutive patients who received postsurgical prophylaxis with warfarin within 24 hours of total knee replacement (TKR) or total hip replacement (THR) surgery and who were referred to and had outpatient follow-up for anticoagulation management in a single-center, university-based antithrombosis clinic from January 1, 1998, to January 1, 2009, were included in the study. Data were obtained from existing inpatient and outpatient medical records and retrospectively reviewed. Patient follow-up and data collection were conducted from the time of admission until 90 days after surgery. RESULTS A total of 400 patients were included in the study; 179 (44.8%) underwent THR and 221 (55.3%) underwent TKR. The mean length of hospital stay was 5.0 ± 1.9 days, and the mean length of warfarin therapy was 50 ± 21 days. The mean time required to reach the target International Normalized Ratio (INR) of 2.0-3.0 was 10.0 ± 9.1 days. The within-patient percentage of INR levels spent in the target range was 28% ± 18%. Objectively confirmed symptomatic venous thromboembolism (VTE) occurred in 16 patients (4%), with 14 events (87.5%) occurring with INR values of ≤2.0 and 2 events (12.5%) occurring with INR values of >2.0. CONCLUSION THR and TKR surgical patients at one institution who were receiving postsurgical VTE prophylaxis with warfarin spent a substantial proportion of time with their INR below the target range and had a high rate of symptomatic VTE.

[1]  M. Duh,et al.  A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery , 2012 .

[2]  Gordon H Guyatt,et al.  Executive Summary Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2012 .

[3]  J. Schein,et al.  Warfarin prophylaxis in patients after total knee or hip arthroplasty – international normalized ratio patterns and venous thromboembolism , 2011, Current medical research and opinion.

[4]  M. Franchini,et al.  Preventing postsurgical venous thromboembolism: pharmacological approaches. , 2011, Seminars in thrombosis and hemostasis.

[5]  E. Nutescu.  Anticoagulation Management Services: Entering a New Era , 2010, Pharmacotherapy.

[6]  L. Cavallari,et al.  Anticoagulation: Effect of a Warfarin Adherence Aid on Anticoagulation Control in an Inner-City Anticoagulation Clinic Population , 2009, The Annals of pharmacotherapy.

[7]  W. Baker,et al.  Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.

[8]  D. Berlowitz,et al.  Measuring quality of oral anticoagulation care: extending quality measurement to a new field. , 2009, Joint Commission journal on quality and patient safety.

[9]  J. Parvizi,et al.  In hospital complications after total joint arthroplasty. , 2008, The Journal of arthroplasty.

[10]  A. Shorr,et al.  Burden of Deep Vein Thrombosis in the Outpatient Setting Following Major Orthopedic Surgery , 2008, The Annals of pharmacotherapy.

[11]  Clifford W Colwell,et al.  Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .

[12]  Stuart B Goodman,et al.  Current state and future of joint replacements in the hip and knee , 2008, Expert review of medical devices.

[13]  F. Anderson,et al.  Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty , 2008, Current medical research and opinion.

[14]  J. Ansell,et al.  Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management , 2008, Expert review of cardiovascular therapy.

[15]  Carol DeFrances,et al.  2006 National Hospital Discharge Survey. , 2005, National health statistics reports.

[16]  S. Kurtz,et al.  Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. , 2007, The Journal of bone and joint surgery. American volume.

[17]  Jay Lin,et al.  Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[18]  Steven Kurtz,et al.  Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. , 2005, The Journal of bone and joint surgery. American volume.

[19]  D. Witt,et al.  Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. , 2005, Chest.

[20]  J. Menzin,et al.  Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study , 2005, The Annals of pharmacotherapy.

[21]  D. Brotman,et al.  Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty , 2004, Thrombosis and Haemostasis.

[22]  R. Brand,et al.  Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. , 2001, The Journal of arthroplasty.

[23]  J. Caprini,et al.  The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. , 1999, Journal of vascular surgery.